# CureDuchenne Ventures

CureDuchenne Ventures is a Venture Capital based in Newport Beach, United States.

## Overview

- **Organization type:** Venture Capital
- **Headquarters:** Newport Beach, United States
- **Region:** North America
- **Address:** Newport Beach, CA, United States
- **Founded:** 2014
- **Assets under management:** Undisclosed
- **Website:** www.cureduchenne.org
- **LinkedIn:** https://www.linkedin.com/company/cureduchenne

## Regulatory record

- **Reports private funds:** No

## About

CureDuchenne is a national nonprofit that funds research to find a cure for Duchenne muscular dystrophy. It uses an innovative venture philanthropy model that funds groundbreaking research, early diagnosis and treatment access, along with education and support programs for families affected by the disease.

## Sectors

- Digital Health
- Healthcare Services

## People

- Debra Miller — Founder & CEO
- Michael G. Kelly — Chief Scientific Officer
- Paul Miller — co-founder

## Questions

### Is CureDuchenne Ventures a traditional venture capital fund?

No. It is the venture-philanthropy arm of a registered nonprofit, not a for-profit fund with limited partners. Because its capital comes from donations rather than institutional investors demanding market-rate returns, the firm can underwrite higher scientific risk and accept longer time horizons. Any financial returns from exits are recycled back into CureDuchenne's grantmaking and research programs rather than distributed to partners.

### Who runs investment decisions at CureDuchenne Ventures?

The firm does not publicly list a dedicated investment team or managing partner. Investment decisions appear to be made by the nonprofit's founder Debra Miller alongside a scientific advisory board of Duchenne researchers and clinicians. This tight, science-first governance model is common in disease-focused venture philanthropy, where the investment committee looks more like a peer-review panel than a traditional GP group.

### Does CureDuchenne Ventures co-invest with outside venture capital firms?

Yes. The firm regularly co-invests alongside traditional biotech venture funds, often as the first institutional capital into a Duchenne-focused startup. Later-stage syndicates have included top-tier life-science investors such as RA Capital and Atlas Venture, with CureDuchenne Ventures bringing patient-community access and disease-specific scientific validation that a generalist biotech fund cannot offer.

## Related profiles

- [Cure8 Ventures](https://altss.com/profile/cure8-ventures)
- [Cure Kids Ventures](https://altss.com/profile/cure-kids-ventures)

---

Last updated: 2026-08-11T15:06:35.052Z

Canonical page: https://altss.com/profile/cureduchenne-ventures

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology